Tempest Therapeutics, Inc. — Director's Dealing 2016

May 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2016-05-10

Reporting Person: CHAPMAN PAUL W.D. (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-05-10	Common Stock	P	3100	$7.37	Acquired	3100	Direct

Footnotes

F1: This Form 4 reflects the purchase of 3,100 shares by Mr. Chapman in the market.